GSK plc
NYSE:GSKDrug Manufacturers - General
-$1.34 today
- Market cap
- $97.53B
- Beta
- 0.29
- P/E (TTM)
- 13.3
- EPS (TTM)
- $1.45
- Dividend yield
- 3.48%
Volume 2.02M
Average 4.07M
GSK Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
GSK plcNYSE: GSK
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of £224.81M fell 80.6% year over year, behind the -34.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 51.4% from the prior quarter. Over 3 fiscal years it compounded at +2.5% a year.
Context
- Depreciation & amortization amounted to 7.1% of revenue in FY2025, down 1.0 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -80.6% toward the trailing-twelve-month pace of -34.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
GBP · from the cash flow
- Latest · FY2025
- 2.31B GBP
- Year-over-year change
- -9.3%
- 4-year CAGR
- +2.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.31B | -9.3% |
| FY2024 | 2024-12-31 | 2.55B | +11.2% |
| FY2023 | 2023-12-31 | 2.29B | +6.8% |
| FY2022 | 2022-12-31 | 2.15B | +1.2% |
| FY2021 | 2021-12-31 | 2.12B | — |
Depreciation & Amortization vs competitors
How GSK compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -34.0% is the lowest of 10, against a peer median of +10.9%.
- Depreciation & amortization amounts to 6.7% of revenue for GSK, versus a peer median of 10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 27.16B DKK | +69.6% | +44.0% | 8.2% | |
| LTM Sep 2026 | $8.09B USD | +9.5% | +2.5% | 8.1% | |
| LTM Jun 2026 | $6.72B USD | +45.9% | +14.3% | 10.1% | |
| LTM Jun 2026 | $6.58B USD | -3.0% | +9.2% | 10.3% | |
| LTM Sep 2026 | $6.41B USD | +29.8% | +3.0% | 10.3% | |
| LTM Jun 2026 | €5.88B EUR | +22.9% | +22.2% | 12.0% | |
| LTM Jun 2026 | $5.34B USD | -11.0% | -7.2% | 9.6% | |
| LTM Jun 2026 | $4.67B USD | -15.5% | +14.8% | 12.2% | |
| LTM Jun 2026 | £2.21B GBP | -34.0% | +2.5% | 6.7% | |
| LTM Jun 2026 | $2.1B USD | +10.9% | +9.5% | 2.6% | |
| Peer median (excluding GSK) | — | +10.9% | +9.5% | 10.1% | |
Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 3.52B | 5.49B | 6.13B | 2.95B | 5.59B |
| Depreciation & Amortization | 2.12B | 2.15B | 2.29B | 2.55B | 2.31B |
| Deferred Income Tax | 0 | (965.72M) | (1.08B) | 0 | 0 |
| Stock-Based Compensation | 343M | 0 | 0 | 344M | 0 |
| Change in Working Capital | 1.39B | (1.67B) | (1.06B) | 2.09B | (608.37M) |
| Accounts Receivables | (1.16B) | (758.78M) | (806.74M) | 340M | 0 |
| Inventory | 51M | (331.35M) | (527.05M) | (294M) | 0 |
| Accounts Payables | 0 | 608.5M | (18.65M) | 0 | 0 |
| Other Working Capital | 2.5B | (1.19B) | 288.39M | 2.04B | (608.37M) |
| Other Non-Cash Items | 584M | 3.16B | 1.61B | (1.38B) | (153.41M) |
| Operating Cash Flow | 7.95B | 8.16B | 7.89B | 6.55B | 7.14B |
| Capital Expenditures | (2.65B) | (1.41B) | (1.63B) | (2.98B) | (1.32B) |
| Acquisitions (Net) | 185M | (3.79B) | (1.72B) | 1.37B | (4.37B) |
| Purchases of Investments | 0 | (177.38M) | (152.9M) | 0 | (89.98M) |
| Sales of Investments | 18M | 294.4M | 2.37B | 21M | 195.62M |
| Other Investing Activities | (1.03B) | (4.43B) | 14.92M | (1.22B) | 1.46B |
| Investing Cash Flow | (1.78B) | (10.88B) | (2.4B) | (1.23B) | (5.72B) |
| Debt Repayment | (2B) | (5.69B) | (2.95B) | (1.17B) | 1.47B |
| Common Stock Issued | 21M | 30.79M | 12.43M | 20M | 14.67M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (4B) | (4.27B) | (2.79B) | (2.44B) | (2.51B) |
| Other Financing Activities | (1.61B) | 11.98B | (341.84M) | (1.14B) | (573.16M) |
| Financing Cash Flow | (7.59B) | 2.05B | (6.07B) | (4.73B) | (1.59B) |
| Effect of Forex Changes | (29M) | (637.97M) | (153.84M) | (54M) | (32.94M) |
| Net Change in Cash | (1.44B) | (1.31B) | (735.58M) | 545M | (206.06M) |
| Free Cash Flow | 5.3B | 6.75B | 6.26B | 3.57B | 5.82B |
GSK plc
NYSE:GSK
Intrinsic Alpha fair value
Locked
Current Price
$48.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.